Form 4: Recursion Pharma Director Sells 170,000 Shares
Insider Transaction Report
Recursion Pharmaceuticals director Blake Borgeson sold 170,000 shares of Class A Common Stock for $3.46 per share.
Summary
- Blake Borgeson, a director of Recursion Pharmaceuticals, Inc. (RXRX), reported a sale of company stock.
- The transaction involved the disposition of 170,000 shares of Class A Common Stock.
- The shares were sold at a price of $3.46 per share.
- Following this transaction, Borgeson beneficially owns 6,259,863 shares of Class A Common Stock.
- The sale was executed on March 3, 2026, pursuant to a Rule 10b5-1 plan.
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a slightly negative signal due to a director selling a substantial number of shares, although the sale was pre-planned under Rule 10b5-1.
Negatives
- A director, Blake Borgeson, sold 170,000 shares of Class A Common Stock.
- The sale price was $3.46 per share.
Risks
- Insider selling by a director could be interpreted by the market as a lack of confidence in the company's future prospects or current valuation, potentially impacting investor sentiment.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that insider sales, especially by directors, are closely watched in the biotechnology and pharmaceutical sectors (where Recursion Pharmaceuticals operates) as they can sometimes precede significant company news or reflect internal perspectives on valuation. However, this specific filing does not provide enough context to draw broader industry conclusions beyond the general observation of insider activity.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Plan | The reported transaction was executed pursuant to a Rule 10b5-1(c) contract, instruction, or written plan for the purchase or sale of equity securities. | 03/03/2026 | This plan allows insiders to pre-arrange sales to avoid accusations of trading on material non-public information, providing a structured approach to share dispositions. |
Stakeholder Impact
- Shareholders: May interpret the director's sale as a negative signal, potentially impacting investor confidence and stock price.
Key Dates
| Date | Description |
|---|---|
| 03/03/2026 | Date of earliest transaction (sale of Class A Common Stock) |
| 03/04/2026 | Signature date of the reporting person's attorney-in-fact |
Recommendation
holdWhile a director selling shares can be a negative signal, the transaction was executed under a Rule 10b5-1 plan, suggesting it was pre-scheduled and not necessarily indicative of new negative information. Without further context on the company's performance or other market factors, a 'hold' recommendation is appropriate, advising investors to monitor future developments.
Keywords
Recursion Pharmaceuticals, RXRX, insider trading, Form 4, stock sale, director, Blake Borgeson, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.